Loading stock data…
EPRX
$7.89+0.09 (+1.15%)
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Eupraxia Pharmaceuticals Inc. in the Healthcare sector is trading at $7.89. The stock is currently 15% below its 52-week high of $9.32, remaining 18.5% above its 200-day moving average. Technical signals show neutral RSI of 67 and bullish MACD crossover, explaining why EPRX maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 67) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.89
Potential Upside
5%
Whystock Fair Value$8.28
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with s...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$434.21M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.42
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-35.29%
Volume
Today's trading volume
266,136
Recent News
Eupraxia Reports Latest 36-Week Results From Resolve Trial
Eupraxia Pharmaceuticals (EPRX.TO) Tuesday reported the latest 36-week results for the highest dose
New Strong Sell Stocks for April 2nd
ACCO, CDE and EPRX have been added to the Zacks Rank #5 (Strong Sell) List on April 2nd, 2026.
Eupraxia Reports Positive Six-Month Data From Eosinophilic Esophagitis Trial
Eupraxia Pharmaceuticals (EPRX.TO) Tuesday reported "positive data" from patients in the two highest
Eupraxia Pharmaceuticals Q4 Loss Widens
Eupraxia Pharmaceuticals (EPRX.TO) overnight Thursday reported a wider fourth-quarter net loss. T
Eupraxia Pharmaceuticals Closes US$63.2M Public Offering Including Full Exercise of Underwriter Option
Eupraxia Pharmaceuticals (EPRX.TO, EPRX) was at last look up 4% in late Friday afternoon trade in Ca